Neonatologie Scan, Table of Contents Neonatologie Scan 2014; 03(02): 139-150DOI: 10.1055/s-0034-1365397 Fortbildung © Georg Thieme Verlag KG Stuttgart · New YorkKoffein zur Behandlung der Frühgeborenenapnoen Authors Axel Hübler Christian Poets Recommend Article Abstract Buy Article(opens in new window) Full Text References Literatur 1 Spitzer AR. Evidence-based methylxanthine use in the NICU. Clin Perinatol 2012; 39 (1) 137-148 2 Dukhovny D et al. Economic evaluation of caffeine for apnea of prematurity. Pediatrics 2011; 127 (1) e146-155 3 Supcun S et al. Caffeine increases cerebral cortical activity in preterm infants. J Pediatr 2010; 156 (3) 490-491 4 Rivkees SA, Wendler CC. Adverse and protective influences of adenosine on the newborn and embryo: implications for preterm white matter injury and embryo protection. Pediatr Res 2011; 69 (4) 271-278 5 Tanaka K et al. Comparative effects of respiratory stimulants on hypoxic neuronal cell injury in SH-SY5Y cells and in hippocampal slice cultures from rat pups. Pediatr Int 2013; 55 (3) 320-327 6 Kumral A et al. Genetic basis of apnoea of prematurity and caffeine treatment response: role of adenosine receptor polymorphisms: genetic basis of apnoea of prematurity. Acta Paediatr 2012; 101 (7) e299-e303 7 Clyman RI, Roman C. The effects of caffeine on the preterm sheep ductus arteriosus. Pediatr Res 2007; 62 (2) 167-169 8 Anderson BJ et al. Caffeine overdose in a premature infant: clinical course and pharmacokinetics. Anaesth Intensive Care 1999; 27 (3) 307-311 9 Ergenekon E et al. Caffeine intoxication in a premature neonate. Paediatr Anaesth 2001; 11 (6) 737-739 10 Schmidt B et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006; 354 (20) 2112-2121 11 Schmidt B et al. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA 2012; 307 (3) 275-282 12 Schmidt B et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007; 357 (19) 1893-1902 13 Francart SJ, Allen MK, Stegall-Zanation J. Apnea of prematurity: caffeine dose optimization. J Pediatr Pharmacol Ther 2013; 18 (01) 45-52 14 Gray PH et al. Caffeine citrate for very preterm infants: Effects on development, temperament and behaviour. J Paediatr Child Health 2011; 47 (04) 167-172 15 Steer PA et al. Periextubation caffeine in preterm neonates: a randomized dose response trial. J Paediatr Child Health 2003; 39 (07) 511-515 16 Scanlon JE et al. Caffeine or theophylline for neonatal apnoea?. Arch Dis Child 1992; 67 (04) 425-428 17 Lee TC et al. Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. Clin Pharmacol Ther 1997; 61 (06) 628-640 18 Schoen K et al. Use of Methylxanthine Therapies for the Treatment and Prevention of Apnea of Prematurity. Paediatr Drugs 2014; 16: 169-177 19 Patel P et al. Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants. Br J Clin Pharmacol 2013; 75 (03) 805-813 20 Natarajan G et al. Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise?. Pediatrics 2007; 119 (05) 936-940 21 Chavez ValdezR et al. Correlation between serum caffeine levels and changes in cytokine profile in a cohort of preterm infants. J Pediatr 2011; 158 (01) 57-64 22 Henderson-Smart DJ, De Paoli AG. Methylxanthine treatment for apnoea in preterm infants. Cochrane Database Syst Rev 2010; (12) CD000140 23 Henderson-Smart DJ, Steer PA. Caffeine versus theophylline for apnea in preterm infants. Cochrane Database Syst Rev 2010; CD000273 24 Martin RJ, Abu-Shaweesh JM. Control of breathing and neonatal apnea. Biol Neonate 2005; 87 (04) 288-295 25 Gannon BA. Theophylline or caffeine: which is best for apnea of prematurity?. Neonatal Netw 2000; 19 (08) 33-36 26 Aiba T et al. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. J Am Coll Cardiol 2005; 45 (02) 300-307 27 Batchvarov VN et al. QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol 2002; 282 (06) H2356-H2363 28 Drici MD, Barhanin J. Cardiac K+ channels and drug-acquired long QT syndrome. Therapie 2000; 55 (01) 185-193 29 Miyata M et al. Dynamic QT/RR relationship of cardiac conduction in premature infants treated with low-dose doxapram hydrochloride. J Perinat Med 2007; 35 (04) 330-333 30 Alvaro R et al. Small preterm infants (less than or equal to 1500 g) have only a sustained decrease in ventilation in response to hypoxia. Pediatr Res 1992; 32 (04) 403-406 31 Yost CS. A new look at the respiratory stimulant doxapram. CNS Drug Rev 2006; 12 (03) 236-249 32 Dani C et al. Brain hemodynamic effects of doxapram in preterm infants. Biol Neonate 2006; 89 (02) 69-74 33 Poets CF, Darraj S, Bohnhorst B. Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants. Biol Neonate 1999; 76 (04) 207-213 34 Sreenan C et al. Isolated mental developmental delay in very low birth weight infants: association with prolonged doxapram therapy for apnea. J Pediatr 2001; 139 (06) 832-837 35 Fischer C et al. Doxapram and hypokalaemia in very preterm infants. Arch Dis Child Fetal Neonatal Ed 2013; 98 (05) F416-F418 36 Greenwood DC et al. Caffeine intake during pregnancy, late miscarriage and stillbirth. Eur J Epidemiol 2010; 25 (04) 275-280 37 Jarosz M, Wierzejska R, Siuba M. Maternal caffeine intake and its effect on pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol 2012; 160 (02) 156-160 38 Laughon SK et al. Caffeine and insulin resistance in pregnancy. Am J Perinatol 2011; 28 (07) 571-578 39 Schmidt RJ et al. Caffeine, selected metabolic gene variants, and risk for neural tube defects. Birth Defects Res A Clin Mol Teratol 2010; 88 (07) 560-569 40 Browne ML et al. Maternal caffeine intake and risk of selected birth defects in the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 2011; 91 (02) 93-101 41 Hentges CR et al. Serum levels of caffeine in umbilical cord and apnea of prematurity. J Pediatr (Rio J) 2010; 86 (02) 137-142 42 Loomans EM et al. Caffeine intake during pregnancy and risk of problem behavior in 5- to 6-year-old children. Pediatrics 2012; 130 (02) e305-e313 43 Santos IS, Matijasevich A, Domingues MR. Maternal caffeine consumption and infant nighttime waking: prospective cohort study. Pediatrics 2012; 129 (05) 860-868 44 Eichenwald EC, Aina A, Stark AR. Apnea frequently persists beyond term gestation in infants delivered at 24 to 28 weeks. Pediatrics 1997; 100 (03) 354-359 45 Comer AM, Perry CM, Figgitt DP. Caffeine citrate: a review of its use in apnoea of prematurity. Paediatr Drugs 2001; 3 (01) 61-79 46 Barrington K, Finer N. The natural history of the appearance of apnea of prematurity. Pediatr Res 1991; 29 (04) 372-375 47 Henderson-Smart DJ. The effect of gestational age on the incidence and duration of recurrent apnoea in newborn babies. Aust Paediatr J 1981; 17 (04) 273-276 48 Peter CS et al. Gastroesophageal reflux and apnea of prematurity: no temporal relationship. Pediatrics 2002; 109 (01) 8-11 49 Poets CF, Langner MU, Bohnhorst B. Effects of bottle feeding and two different methods of gavage feeding on oxygenation and breathing patterns in preterm infants. Acta Paediatr 1997; 86 (04) 419-423 50 Ruggins NR. Pathophysiology of apnoea in preterm infants. Arch Dis Child 1991; 66 (01) 70-73 51 Milner AD et al. Upper airways obstruction and apnoea in preterm babies. Arch Dis Child 1980; 55 (01) 22-25 52 Waggener TB et al. Mixed and obstructive apneas are related to ventilatory oscillations in premature infants. J Appl Physiol 1989; 66 (06) 2818-2826 53 Martin RJ, Abu-Shaweesh JM, Baird TM. Apnoea of prematurity. Paediatr Respir Rev 2004; 5: 377-382 54 Gauda EB et al. Maturation of peripheral arterial chemoreceptors in relation to neonatal apnoea. Semin Neonatol 2004; 9 (03) 181-194 55 Poets CF. Atemregulation beim Neugeborenen. In: Jorch G, Hübler A. Neonatologie – Die Medizin des Früh- und Reifgeborenen. Stuttgart: Thieme; 2010: 181-184 56 Bandla HP et al. Protein kinase C modulates ventilatory patterning in the developing rat. Am J Respir Crit Care Med 1999; 159 (03) 968-973 57 Dreshaj IA et al. CO2-induced prolongation of expiratory time during early development. Respir Physiol 1999; 116 (02) 125-132 58 Dreshaj IA, Haxhiu MA, Martin RJ. Role of the medullary raphe nuclei in the respiratory response to CO2 . Respir Physiol 1998; 111 (01) 15-23 59 Duara S, Silva NetoG, Claure N. Role of respiratory muscles in upper airway narrowing induced by inspiratory loading in preterm infants. J Appl Physiol 1994; 77 (01) 30-36 60 Wulbrand H, Von Zezschwitz G, Bentele KH. Submental and diaphragmatic muscle activity during and at resolution of mixed and obstructive apneas and cardiorespiratory arousal in preterm infants. Pediatr Res 1995; 38 (03) 298-305 61 Poets CF, Samuels MP, Southall DP. On sudden severe bradycardia secondary to hypoxemia. Pediatr Pulmonol 1992; 12 (01) 59-60 62 Poets CF et al. Determinants of lung volume in spontaneously breathing preterm infants. Am J Respir Crit Care Med 1997; 155 (02) 649-653 63 Numa AH, Newth CJ. Anatomic dead space in infants and children. J Appl Physiol 1996; 80 (05) 1485-1489 64 Fleming PJ, Bryan AC, Bryan MH. Functional immaturity of pulmonary irritant receptors and apnea in newborn preterm infants. Pediatrics 1978; 61 (04) 515-518 65 Stransky A, Szereda-Przestaszewska M, Widdicombe JG. The effects of lung reflexes on laryngeal resistance and motoneurone discharge. J Physiol 1973; 231 (03) 417-438 66 Pickens DL, Schefft G, Thach BT. Prolonged apnea associated with upper airway protective reflexes in apnea of prematurity. Am Rev Respir Dis 1988; 137 (01) 113-118 67 Kattwinkel J. Neonatal apnea: pathogenesis and therapy. J Pediatr 1977; 90 (03) 342-347 68 Poets CF et al. Reduced haemoglobin levels in infants presenting with apparent life-threatening events – a retrospective investigation. Acta Paediatr 1992; 81 (04) 319-321 69 Rigatto H, Brady JP. Periodic breathing and apnea in preterm infants. II. Hypoxia as a primary event. . Pediatrics 1972; 50 (02) 219-228 70 Poets CF, Pauls U, Bohnhorst B. Effect of blood transfusion on apnoea, bradycardia and hypoxaemia in preterm infants. Eur J Pediatr 1997; 156 (04) 311-316 71 Westkamp E et al. Blood transfusion in anemic infants with apnea of prematurity. Biol Neonat 2002; 82 (04) 228-232 72 Henderson-Smart DJ, Steer P. Methylxanthine treatment for apnea in preterm infants. Cochrane Database Syst Rev 2001; CD000140 3 73 Perlman JM, Volpe JJ. Episodes of apnea and bradycardia in the preterm newborn: impact on cerebral circulation. Pediatrics 1985; 76 (03) 333-338 74 Poets CF et al. The relationship between bradycardia, apnea, and hypoxemia in preterm infants. Pediatr Res 1993; 34 (02) 144-147 75 Poets CF, Roth B, Bohnhorst B. Therapie idiopathischer Apnoen, Bradykardien und Hypoxämien bei Frühgeborenen. AWMF 2009; Nr. 024/013 (GNPI) 76 Vatlach S et al. Safety Profile Comparison between Extemporaneous and a Licensed Preparation of Caffeine Citrate in Preterm Infants with Apnea of Prematurity. Neonatology 2013; 105 (02) 108-111 77 Henderson-Smart DJ, Davis PG. Prophylactic methylxanthines for endotracheal extubation in preterm infants. Cochrane Database Syst Rev 2010; CD000139 12 78 Mathew OP. Apnea of prematurity: pathogenesis and management strategies. J Perinatol 2011; 31 (05) 302-310
